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 2 
Abstract 20 
A silicone elastomer vaginal ring device providing sustained release over 28 days of the 21 
antiretroviral microbicide dapivirine has recently completed Phase III clinical testing and 22 
showed moderate protection against HIV acquisition. Here, for the first time, and in support 23 
of the product licensure program, we report the impact of dapivirine packing polymorphism 24 
on the in vitro performance of the 25 mg dapivirine ring product. Thermal, particle size, 25 
powder x-ray diffraction and thermodynamic solubility analyses of dapivirine polymorphic 26 
forms I and IV, both of which are persistent at room temperature and with form I being the 27 
thermodynamically stable form, were conducted for micronized and non-micronized 28 
materials. Matrix-type silicone elastomer vaginal rings were manufactured and the impact 29 
of dapivirine polymorphism on key in vitro parameters (compression and tensile behaviour; 30 
content assay; in vitro release; residual content assay) was investigated. The data 31 
demonstrate that dapivirine packing polymorphism has no significant impact on in vitro 32 
performance of the 25 mg dapivirine vaginal ring. 33 
 3 
1. Introduction 34 
Many solid drug substances exist in different crystalline forms – known as packing 35 
polymorphs – that differ in their physical properties.1 In some cases, these different 36 
crystalline forms of the drug substance can significantly affect the pharmacological 37 
performance of the drug product. One of the most widely reported examples is the influence 38 
of polymorphism on the oral bioavailability of the antiretroviral drug ritonavir.2,3 Ritonavir 39 
exists in two major crystalline forms – forms I and II. In 1998, the unexpected appearance 40 
of the more stable (and therefore less soluble) form II during routine testing of the drug led 41 
to compromised oral bioavailability of the drug and ultimately removal of the oral capsule 42 
formulation from the market. Since this incident, the U.S. Food and Drug Administration 43 
(FDA) has focused increased attention on the potential impact of drug polymorphism on 44 
the performance of drug products and the measures taken to ensure that physical properties 45 
to not change during shelf life. It is therefore imperative that polymorphism is investigated 46 
during the drug product development process. Both the FDA and the International Council 47 
for Harmonisation (ICH) have published regulatory documents addressing pharmaceutical 48 
polymorphism.4–6 49 
 50 
Dapivirine (DPV) is an experimental non-nucleoside reverse transcriptase inhibitor 51 
(NNRTI) that is currently being developed as a vaginal microbicide for prevention of 52 
sexual transmission of human immunodeficiency virus type 1 (HIV-1).7–12 A wide range 53 
of formulation strategies have been reported for vaginal administration of DPV,13–18 the 54 
most advanced and the most promising of which are silicone elastomer vaginal rings.19–33 55 
Two Phase III efficacy studies – The Ring Study (IPM027) and APSIRE (MTN-020) – 56 
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involving more than 4,500 women volunteers across southern and eastern Africa have 57 
recently been completed, designed to support licensure of a monthly matrix-type silicone 58 
elastomer vaginal ring containing 25 mg micronized DPV intended for 28-day continuous 59 
use (DPV Ring-004). The studies showed approximately 30% reduced incidence of HIV 60 
infection in women compared to a placebo, the first time two studies have confirmed 61 
statistically significant efficacy for a HIV microbicide.27,33 The lower than anticipated 62 
protection rates were attributed to poor user adherence, an ongoing problem that has 63 
adversely affected clinical testing of HIV microbicides.33–42 Post-hoc analyses of the DPV 64 
ring clinical data in The Ring Study and ASPIRE have revealed that rates of protection are 65 
very significantly increased (>60%) in sub-groups demonstrating increased adherence.27,33  66 
 67 
Three crystalline polymorphic forms of DPV have been identified – forms I, II and IV 68 
(Figure 1).22 A dichloromethane hemi-solvate stable up to 130 °C was originally identified 69 
as polymorphic form III. However, dichloromethane is no longer used in the DPV 70 
manufacturing process. Therefore, further work with this form was no longer relevant and 71 
was not pursued. The current method for chemical synthesis of DPV reproducibly produces 72 
the drug in packing polymorphic form I, which is the most stable form at room temperature 73 
22. To date, form I has been confirmed for all manufactured batches of micronized DPV 74 
used in clinical development 22.  75 
 76 
DPV form I undergoes a solid-solid transition to form II at ~100 °C (Figure 2; can range 77 
from 96.9 to 110.3 °C), as evidenced by a small endothermic transition in the differential 78 
scanning calorimetry (DSC) trace.20,23,26 The variation in solid-solid transition temperature 79 
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between form I and form II has been observed for different lots of form I; however, it could 80 
not be attributed to a single phenomenon. Upon further heating, DPV form II undergoes 81 
crystalline melting at ~220 °C (ranges from 217.9 to 226.9 °C), and then, upon cooling 82 
below 100 °C, form II instantaneously reverts to form I. Form I and form II are therefore 83 
related enantiotropically with a transition temperature close to 100 °C. The same 84 
polymorphic interconversion and crystalline melt transitions are also observed when DPV 85 
is incorporated into the silicone elastomer matrix of the Dapivirine Ring-004, indicating 86 
that there are no significant drug-polymer interactions.23  87 
 88 
During development, DPV has also been observed in crystalline polymorphic form IV, 89 
which is stable at room temperature and forms when dapivirine is recrystallized from 90 
methanol at higher temperatures (Figure 1). Upon heating, it exhibits two endothermic 91 
transitions at 212 and 221 °C corresponding to transformation of form IV to form II and 92 
crystalline melting of form II, respectively (Figure 1).  93 
 94 
In order to meet the requirements of the regulatory agencies, it is important to assess how 95 
polymorphism affects drug product performance. Surprisingly, this issue seems not to have 96 
been reported – at least in the scientific literature – for other vaginal ring products, despite 97 
an explicit understanding that different polymorphic forms of a drug can exhibit 98 
significantly different solubilities in the polymeric matrix and potentially result in different 99 
drug permeation rates. Since forms I and IV are the only DPV polymorphs stable at room 100 
temperature (which is the desired storage temperature of the vaginal ring product), this 101 
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study was conducted to evaluate the thermal properties and in vitro performance of vaginal 102 
rings containing 25mg DPV as either the form I or the form IV polymorph.  103 
 104 
2. Materials and methods 105 
2.1. Materials 106 
Non-micronized DPV form I and form IV and micronized form I were supplied by S.A. 107 
Ajinomoto OmniChem n.v. (Wetteren, Belgium). DPV form IV was micronized by 108 
JetPharma (Balerna, Switzerland). MED-4870 addition-cure silicone elastomer (Parts A 109 
and B) and MED-360 silicone oil were purchased from NuSil Technology (Carpinteria, 110 
CA, USA). Potassium dihydrogen orthophosphate, potassium hydroxide and urea (AnalaR, 111 
analytical reagent grade) were purchased from VWR International Ltd. (Dublin, Ireland). 112 
Norethindrone was purchased from LGM Pharma, (Nashville, TN, USA). HPLC-grade 2-113 
propanol (IPA) and acetonitrile, phosphoric acid (85% w/w in water), Tween 80, sodium 114 
chloride, calcium hydroxide, bovine serum albumin, lactic acid, acetic acid and glucose 115 
were all purchased from Sigma-Aldrich (Gillingham, UK). A Millipore Direct-Q 3 UV 116 
Ultrapure Water System (Watford, UK) was used to obtain HPLC-grade water. Simulated 117 
vaginal fluid + 0.2% (w/v) Tween 80 (SVF+Tween) release media was prepared according 118 
to a previously described method followed by addition of the Tween 80 component.43   119 
 120 
2.2 Thermal analysis 121 
The thermal stability of DPV forms I and IV were analysed by thermogravimetric analysis 122 
(TGA) using a TA Instruments Q50™ Thermogravimetric Analyser and a TA Instruments 123 
Differential Scanning Calorimeter Q20™ (TA Instruments, UK). For these experiments, 124 
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5–10 mg of sample was heated from 25 to 300 °C at 10 °C /min in an open aluminium pan 125 
under a nitrogen atmosphere. For differential scanning calorimetry (DSC) experiments, 5–126 
7 mg of sample (either pure polymorph or 10% w/w DPV-loaded silicone elastomer) 127 
underwent heat-cool-heat cycles between 20 and 235 °C using a heating rate of 10 °C per 128 
min. The temperature range was selected to encompass the molding temperatures 129 
commonly used to fabricate DPV matrix-type rings via injection molding processes (160–130 
180 °C). For each sample, onset temperature (°C), peak temperature (°C) and enthalpy 131 
(ΔH, J/g) values were recorded for each thermal transition observed. 132 
 133 
2.3. Particle size analysis  134 
The particle size distributions (PSDs) of micronized and non-micronized forms of both 135 
polymorphs were characterised using a Mastersizer 3000 (Malvern , UK) instrument fitted 136 
with an AERO S accessory. Approximately 1 g of material was weighed and added to the 137 
Venturi. Using an air pressure of 2 Bar(g), the hopper gap was sequentially raised in 0.5 138 
mm steps from 0.5 mm and the feed rate increased to between 30 and 60% to provide a 139 
reasonable flow of powder into the instrument. The target obscuration range was 1–4 %. A 140 
minimum of six measurements of each sample were performed to give an estimate of the 141 
variability about the measurement. 142 
 143 
2.4. Powder X-ray diffraction 144 
Powder X-ray diffraction (PXRD) patterns of non-micronized and micronized DPV form 145 
I and IV powders were obtained using a X’PERT Pro MPR X-ray diffractometer 146 
(PANalytical Ltd., UK). Samples were pressed onto a zero background holder so that a 147 
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smooth, flat surface was achieved and mounted in a rotating sample holder. Samples were 148 
exposed to CuKα radiation (40 kV, 40 mA), scanned in continuous mode across the 2θ 149 
angular range of 3.0–90.0o with a step size of 0.016o.    150 
 151 
2.5. Microscopy analysis 152 
Digital microscopy was performed using a Keyence VHX-700F series Digital Microscope 153 
(Keyence Limited, UK) fitted with an RZ 20–200x wide-range zoom lens. A small sample 154 
was dusted onto a section of adhesive tape to provide a thin layer of powder for particle 155 
morphology (shape and size) evaluation. 156 
 157 
2.6.  Ring manufacture 158 
Matrix-type vaginal rings containing 25 mg micronized and non-micronized DPV form I 159 
or form IV dispersed in MED-4870 silicone elastomer were manufactured using a 160 
Babyplast™ 6/10P injection molding machine (Chronoplast, Spain). DPV MED-4870 Part 161 
A premixes (100 g) were prepared by accurately weighing appropriate quantities of MED-162 
4870 (97.5% w/w), MED-360 silicone oil (2.1875% w/w) and DPV (0.3125% w/w) into a 163 
sealed polypropylene container before mixing at 3000 rpm for 3 min in a DAC-150 FVZ-164 
K Speedmixer™ (Hauschild, Germany). Part B premixes were manufactured using the 165 
same protocol. Four 100 g portions of premix A and premix B were prepared (800 g in 166 
total) for each DPV polymorph formulation. Premixes were stored at 4 °C until use. 167 
Immediately prior to injection molding, ~100 g portions each of Part A premix and Part B 168 
premix were sequentially added to a large plastic Speedmixer™ container until ~400 g in 169 
total had been transferred. The material was handmixed for 30 s, speedmixed at 2350 rpm 170 
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for 30 s and further speedmixed for 60 s at 1800 rpm. The silicone elastomer mix was 171 
transferred to a Babyplast™ cartridge which was then fitted into the Babyplast™ injection 172 
molding machine. Rings were manufactured at 185 °C for 60 s. 173 
 174 
2.7. Ring appearance and weight 175 
Ring weight, colour, external diameter (ExD) and cross-sectional diameter (CSD) were 176 
recorded in order to assess the consistency of ring physical parameters. Ten rings from 177 
each DPV polymorph formulation were randomly selected and evaluated. CSD and ExD 178 
were measured using digital callipers (RS Components, UK). Care was taken not to 179 
compress the ring during measurement. 180 
 181 
2.8. Mechanical testing 182 
In the absence of a ratified international standard on the mechanical testing of vaginal rings, 183 
the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research 184 
(CDER) have published nonbinding recommendations to industry in respect of tests for 185 
vaginal microbicide drug product specification, which include the mechanical testing of 186 
ring devices.44 Here, as part of ongoing efforts to establish practical test methods, we have 187 
applied mechanical test methods to vaginal rings based on the minimum requirements and 188 
test methods used for reusable silicone rubber contraceptive diaphragms, as described in 189 
ISO-8009:2014. 190 
 191 
Shore A Hardness testing, also known as durometer testing, was performed on five rings 192 
randomly selected from each DPV polymorph production run. Measurement was carried 193 
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out using a Sauter HBA 100-0 graduated dial durometer (Sauter, Switzerland) calibrated 194 
for Shore A hardness (arbitrary units). During testing the rings were placed on an 195 
unyielding, flat surface. With the durometer held in a vertical position, the instrument’s 196 
indentor was pressed on the uppermost surface of the ring in a constant movement without 197 
shocks until the presser foot was parallel to the ring surface. The maximum deflection on 198 
the dial (0–100), representing the Shore Hardness was recorded. Four individual 199 
measurements per ring were recorded. 200 
 201 
Compression testing was performed using a TA.XTplus Texture Analyser (Stable 202 
Microsystems, UK). Rings previously selected for non-destructive durometer testing were 203 
placed in the appropriate holder and analysed in compression mode using a test speed of 2 204 
mm/s and a target distance of 5.0 mm. Six compression cycles were performed, and the 205 
last five values for the maximum compressive force exerted by the texture analyser 206 
recorded. The first value is not recorded to allow the ring to stabilize in the holder during 207 
the first compression cycle. 208 
 209 
Tensile strength testing was also performed using the TA.XTplus Texture Analyser. Rings 210 
were placed around upper and lower tensile grips and analysed in tension mode with a test 211 
speed of 10 mm/s and a target force of 5 kg. The pass/fail criterion for tensile strength 212 
testing was set at 5 kg i.e. if the ring withstood a force equivalent to 5 kg without rupture 213 
then it was deemed acceptable.  214 
 215 
2.9. In vitro release testing 216 
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Twenty-four samples of each ring formulation were selected for in vitro release testing 217 
over a 30-day period – twelve rings for release into a 1:1 mixture of IPA+H2O and twelve 218 
for release into SVF+Tween. Both media have been used routinely for in vitro release 219 
testing of silicone elastomer vaginal rings, and other vaginal formulations, containing 220 
highly lipophilic poorly water-soluble antiretroviral microbicides, including 221 
DPV.17,19,20,23,25,26,31,45–47. IPA/water is commonly used as a performance test to predict and 222 
monitor the consistency in manufacturing. SVF is intended to mimic the chemical 223 
composition of vaginal fluid, including pH and osmolarity matched to normal vaginal 224 
fluid.43 However, solubility of DPV in SVF is impractically low (< 1 µg/mL),22,46 and, as 225 
a result, in vitro release from vaginal rings into this medium does not correlate with in vivo 226 
release (as measured by residual drug content following clinical use). By comparison, use 227 
of SVF + 0.2% w/v Tween 80 closely mimics in vivo release,27,48 and its use has been 228 
supported by regulatory authorities. 229 
 230 
On Day 0, each ring was placed into a 250 mL glass, screw-top bottle containing 200 mL 231 
of either IPA+H2O or SVF+Tween release medium and stored in a temperature-controlled 232 
orbital shaking incubator (37˚C, 60 rpm, 25 mm orbital throw). The release medium was 233 
sampled and completely replaced (100 mL) daily, with the exception of weekends where 234 
200 mL was added. Drug release was quantified by reverse-phase HPLC with UV detection 235 
(Section 2.11).  236 
 237 
2.10. Content assay and residual content testing 238 
 12 
Both the total DPV content of manufactured rings and the residual content of rings after in 239 
vitro release testing were assessed (n=6 per formulation per test). Rings were weighed and 240 
then cut in half along the length of the ring. The ring halves were immediately transferred 241 
into individually labelled 250 mL glass flasks containing 100 mL acetone. Flasks were 242 
sealed and placed in a temperature-controlled orbital shaking incubator (37 °C, 60 rpm, 25 243 
mm orbital throw). After 24 h, the flasks were removed and allowed to cool to room 244 
temperature. A 1.00 mL aliquot of the acetone extraction solution was transferred to a 100 245 
mL volumetric flask using a positive displacement pipette and diluted to volume with 246 
methanol. Samples were allowed to stand at ambient temperature for 1 h before final 247 
dilution to volume with methanol. Samples were transferred to HPLC vials and analysed 248 
against standard solutions of known DPV concentration.  249 
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2.11. Solubility determination 250 
Thermodynamic solubility of DPV (form 1 and form IV, micronised and non-micronised) 251 
was measured using the shake-flask method at 37 °C in both SVF+0.2% w/w Tween and 252 
1:1 v/v IPA/water mixture. For SVF/Tween measurement, ~5 mg DPV was added to a 253 
glass vial followed by 5.00 mL SVF/Tween; for IPA/water measurement, ~40 mg DPV 254 
was added to a glass vial followed by 5.00 mL IPA/water. The sealed vials were placed in 255 
an orbital shaking incubator for 72 hr. While still in the incubator but with shaking stopped, 256 
1.00 mL and 100 µL volumes of the saturated SVF/Tween and IPA/water solutions, 257 
respectively, were sampled from the vials using suitable micropipettes and placed in new 258 
glass vials, taking care not to sample the settled excess solid drug layer at the bottom of 259 
each vial. SVF/Tween samples were subsequently diluted twofold for HPLC analysis, 260 
while IPA/water samples were diluted by a factor of 100. Drug concentrations were 261 
subsequently quantified by HPLC. In a similar fashion, the solubilities of both DPV form 262 
1 and form IV (micronized only) were measured in aqueous media at different pH values 263 
– 0.1M HCl, 0.01M HCl, pH2 (KCl/HCl), pH4 (acetate buffer), pH6 (phosphate buffer), 264 
pH8 (phosphate buffer). For each solubility measurement, the residual solids were analyzed 265 
by PXRD to determine the extent of form conversion during the solubility analysis and to 266 
ensure the results reflect the true solubility of each form. 267 
 268 
2.12. HPLC Analysis 269 
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Samples for DPV content analysis in rings were analysed on a Waters HPLC system 270 
(Waters Corporation, Dublin, Ireland) consisting of a 1525 Binary HPLC pump with an in-271 
line degasser AF unit, 1500 column heater, 717 Plus Autosampler and a 2487 dual 272 
wavelength absorbance detector. 10 µL of each content sample was injected onto a 273 
Kromasil C18 HPLC column (150 mm x 4.6 mm, 5 µm particle size). Column temperature 274 
was maintained at 25 °C and isocratic elution was performed using a mobile phase of 75% 275 
HPLC-grade methanol and 25% water with a flow rate of 0.75 mL/min and a run time of 276 
15 min. DPV was detected at 257 nm after approximately 10.8 min.   277 
 278 
In vitro release samples (25 µL) were injected onto a Thermo Scientific BDS Hypersil™ 279 
C18 HPLC column (150 mm x 4.6 mm, 3 µm particle size) fitted with a guard column. The 280 
column was held at 45 °C and isocratic elution was performed using a mobile phase of 45% 281 
HPLC-grade acetonitrile and 55% phosphate buffer (pH 3.0; 7.7 mM) with a run time of 8 282 
min. DPV was detected at 240 nm after 6.1 min. 283 
 284 
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2.12. Statistical analyses 285 
Where appropriate, data sets were analysed using a one-way ANOVA followed by post-286 
hoc analysis using the Tukey-Kramer multiple comparisons test. Analysis was conducted 287 
using GraphPad Prism software and significance was noted for a P value of less than 0.05: 288 
* = significant (0.01 < P < 0.05), ** = very significant (0.001 < P < 0.01), *** = extremely 289 
significant (P < 0.001), ns = not significant (P > 0.05). 290 
 291 
The similarity factor (f2) – a logarithmic reciprocal square root transformation of one plus 292 
the mean squared (the average sum of squares) differences of drug percent dissolved 293 
between the test and the reference products – was calculated for ring dissolution data using 294 
Equation 1.49,50 The similarity factor fits the result between 0 and 100. It is 100 when the 295 
test and reference profiles are identical and tends to 0 as the dissimilarity increases. FDA 296 
and EMEA recommend that two dissolution profiles are similar when f2 has a value 297 
between 50 and 100 following testing of at least 12 individual dosage units. 298 
Equation 1.       299 
f2 = 50× log 1+
1
n Rj – Tj
2
j=1
n
∑
⎡
⎣⎢
⎤
⎦⎥
−0.5
×100
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟
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3. Results and Discussion 300 
3.1. Thermal analysis 301 
DPV form I and form IV polymorphs were initially tested using TGA to establish their 302 
thermal stability over the range of temperatures encountered during ring manufacture via 303 
injection molding. Both polymorphs were stable up to temperatures around 240 °C, with 304 
total percent weight loss less than 0.5% at 240 °C for both polymorphic forms (data not 305 
shown). The polymorphs were then examined by DSC using a heat-cool-heat cycle 306 
between 20 and 235 °C. Representative thermograms for the non-micronized forms of DPV 307 
form I and form IV are presented in Figure 2A and 2B, respectively. Table 1 displays the 308 
mean onset peak temperature (°C), the peak maximum temperature (°C) and the enthalpy 309 
(J/g) for each transition recorded in the thermograms.  310 
 311 
Non-micronized DPV form I, the most stable polymorphic form of the compound at room 312 
temperature and the form produced in the synthesis of DPV, displayed characteristic 313 
melting endotherms at 101 °C and 220 °C during the first heat cycle (Figure 2A), attributed 314 
to the solid-solid I→II polymorphic transformation and the form II crystalline melt, 315 
respectively.20,22,23 Upon cooling of this melt, an endothermic step-like shift associated 316 
with formation of amorphous DPV was observed around 80 °C. The second heat cycle then 317 
showed a glass transition (Tg) with amorphous relaxation close to 80 °C, followed by an 318 
exothermic recrystallization transition at 163 °C and the form II melt endotherm at 220 °C. 319 
Similar thermal behaviour was observed for micronized DPV form I (DSC trace not shown, 320 
but data presented in Table 1). 321 
 322 
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By comparison, the non-micronized DPV form IV showed two sharp melting endotherm 323 
transitions, one at 206 °C attributed to the solid-solid IVII transition and the other at 220 324 
°C due to crystalline melting of form II (Figure 2B). Micronized DPV form IV displayed 325 
a broader and smaller IVII endothermic transition at ~190 °C compared to that observed 326 
for the non-micronized form IV material (DSC trace not shown, but data presented in Table 327 
1), attributed to the smaller particle size of the micronized material and/or changes in 328 
crystallinity induced during the micronization process. 329 
 330 
3.2. Particle size distribution 331 
The PSDs of DPV form I and form II polymorphs are presented in Figure 3 for both non-332 
micronized (nm) and micronized (m) material. The distributions were unimodal (modal 333 
particle diameters for forms I(nm), IV(nm), I(m) and IV(m) were 163, 76, 5.9 and 5.2 µm, 334 
respectively), except for an additional second smaller peak at 67 µm for the form I(m) 335 
material. A summary of the d90, d50 and d10 values are presented in Table 2 alongside values 336 
quoted in supplied certificates of analysis (where available). The data in Table 2 indicates 337 
that the experimentally determined PSD values for non-micronized DPV form I were 338 
slightly larger than the values stated in the certificate of analysis, which may be due to 339 
slight differences in the method of analysis or powder sampling protocols. In particular, 340 
for larger particle size materials, sampling protocols can have a greater influence on the 341 
measured value. After micronization, the particle size distributions for both polymorphs 342 
were similar, with an overall tendency towards slightly smaller particles observed for the 343 
form IV sample, as evidenced both by the overlap of the distributions (Figure 3B) and the 344 
similarity of the values for d90, d50 and d10 (Table 2). The other experimentally determined 345 
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particle size distribution values were in good agreement with those specified on the 346 
certificates of analysis. 347 
 348 
3.3. Powder X-ray diffraction 349 
The X-ray diffraction traces for non-micronized and micronized DPV form I and form IV 350 
materials are presented in Figure 4. Both DPV polymorphs are characterised by sharp 351 
diffraction peaks confirming the highly crystalline nature of the materials. No significant 352 
amorphous content was observed as indicated by the absence of broad peaks and halos. 353 
Comparison of traces obtained for the non-micronized and micronized forms of the same 354 
polymorph demonstrate a high degree of similarity with regard to peak positions, indicating 355 
that the micronization process does not significantly alter the crystal form of either 356 
polymorph. However, minor differences in peak intensities were observed, and may be due 357 
to a combination of factors including the particle (crystallite) size, orientation of the 358 
crystals (preferred or random), amount of powder applied to the background sample holder, 359 
or differences in powder packing within the sample holder. Both the non-micronized 360 
(Figure 4A) and micronized (Figure 4B) DPV form I diffraction patterns showed 361 
significant differences in diffraction peak positions when compared to the form IV 362 
materials. In particular, DPV form I traces exhibited distinct diffraction peaks at 2θ = 5.2° 363 
and 10.3° not present in the form IV diffraction patterns. 364 
 365 
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3.4. Microscopy 366 
Representative micrographs of micronized and non-micronized crystals of DPV form I and 367 
IV are presented in Figure 5. The non-micronized materials showed large and highly 368 
crystalline primary particles in the range of 50–350 µm (Figures 5A and 5B). DPV form 369 
IV has a higher proportion of smaller crystals in the <100 µm range compared to DPV form 370 
I, as confirmed by particle size distribution analysis (Figure 3). The micrographs of the 371 
micronized DPV materials displayed particles significantly smaller in size (mostly <10 372 
µm). Although the majority of the micronized material was present as small primary 373 
particles, some larger agglomerations of particles were also visible.  374 
 375 
3.5. Ring appearance and weight 376 
All manufactured rings were free from visible foreign matter and had an off-white opaque 377 
appearance consistent with uniform distribution of the white DPV powder throughout the 378 
otherwise transparent silicone elastomer matrix. Mean ring weight, ExD and CSD for each 379 
form I and form IV ring manufacturing batch (n=5 per batch) are recorded in Table 3. All 380 
rings had weights ~8.0 g, CSDs ~7.6 mm and ExDs ~56.4 mm.  381 
 382 
3.6. Mechanical Testing 383 
Shore A Hardness measurements, recorded for sample rings from each manufacturing 384 
batch and presented in Table 4, are close to 65. The product profile for MED-4870 states a 385 
Shore A Hardness value of 70 for samples cured at 165°C (ASTM D2240). The differences 386 
observed here are attributed to differences in the cure time temperature profile and the other 387 
ingredients included in the formulation, which can have an effect on the mechanical 388 
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performance of the silicone elastomer. Although Shore A hardness measurement is 389 
commonly used in the rubber industry as a standard indicator of mechanical performance, 390 
it is regarded as a basic test and can provide only limited information regarding changes to 391 
the mechanical properties of the rings. Since the ring surface is curved, the test performed 392 
does not conform to ASTM D2240 or ISO 868:2003 testing standards for shore hardness, 393 
which require test specimens to have a flat surface and be at least 6 mm (1/4 in) thick.  394 
 395 
Compression testing to measure the maximum force required to compress a ring a distance 396 
of 5 mm vertically was also performed for each ring formulation batch (n=5). The results, 397 
presented in Figure 6, show that the mean maximum force required for compression of the 398 
DPV(m) form I and form IV rings was similar for all manufacturing batches. No significant 399 
batch-to-batch variability between rings of the same formulation was observed. Statistical 400 
analysis confirmed that all ring batches tested had statistically similar mechanical 401 
properties. 402 
 403 
Tensile strength analysis was performed to assess the integrity of the rings on application 404 
of a force equivalent to 5 kg. Ten rings of each formulation were analysed. All rings were 405 
able to withstand a force equivalent to 5 kg without rupture (data not shown). This arbitrary 406 
5 kg value has been used in the testing of other vaginal ring products (unpublished data). 407 
In clinical use, however, vaginal ring devices are not likely to undergo extensive tensile 408 
deformation. Therefore, the test is primarily used as a quality performance measure for 409 
comparison of different ring formulations and manufacturing processes. 410 
 411 
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3.7. In vitro release  412 
Mean daily and cumulative release versus time plots for both DPV forms I and IV from 413 
matrix-type vaginal rings into IPA+H2O and SVF+Tween media are presented in Figure 7. 414 
The declining daily release values with time (Figures 7A and 7B) are indicative of t½ 415 
kinetics and typical of permeation-controlled drug delivery systems comprising non-416 
biodegradable polymers containing excess solid drug within the matrix.20,23,51,52 Daily DPV 417 
release values were greater for release into IPA+H2O compared with SVF+Tween across 418 
all time points and for both form I and form IV rings, reflecting the higher solubility of 419 
DPV in the solvent/water system. Mean day 1 release values for DPV into IPA+H2O were 420 
2459 and 2564 µg for form I and IV rings, respectively, decreasing to 191 and 183 µg, 421 
respectively, on day 30. Thus, the d1/d30 release ratios for this release medium were 12.9 422 
and 14.0 for form I and IV rings, respectively. Use of SVF+Tween as the release medium 423 
produced significantly different (p-value < .00001) day 1 mean release values for the form 424 
I and IV rings (349 and 578 µg, respectively), while mean day 30 release values were more 425 
similar (116 and 106 µg, respectively; p-value .000019) (Figure 7B); the corresponding 426 
d1/d30 release ratios were 3.0 and 5.5, respectively. It is therefore apparent that the 427 
SVF+Tween release medium blunts the day 1 in vitro release value relative to the day 30 428 
value, compared with the IPA+H2O release medium. In general, greater variability is 429 
observed with the SVF+Tween daily release values compared to those measured using 430 
IPA+H2O, reflecting differences in solvating power between the release media. 431 
 432 
Release rates (µg /day0.5) and coefficients of correlation (r2) obtained from linear regression 433 
analysis of the cumulative DPV release vs. root time plots are presented in Table 5.  434 
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 435 
Comparing the release between polymorphs reveals that the profiles are similar, with 436 
almost identical release into both release media. The only difference of note is increased 437 
DPV release over the first three days into SVF+Tween for the form IV polymorph (Figure 438 
7B). Since there is no significant difference in SVF+Tween solubility between the 439 
polymorphs (Table 6), possible explanations include differences in silicone elastomer 440 
solubility between the two forms of DPV, or differences in drug distribution at the surface 441 
of the ring devices. Given that much greater variability in drug concentrations are observed 442 
in vaginal ring pharmacokinetic studies,28,30,53–55 it is highly unlikely that these relatively 443 
small differences in in vitro release over early timepoints would be clinically significant. 444 
Comparing the line equation gradients of the cumulative release lines highlights the small 445 
differences observed in terms of the release between different polymorphs. This was 446 
confirmed by calculating the similarity factor (f2) which has been recommended by the 447 
FDA for dissolution profile comparison.50,56 As the mean cumulative DPV release did not 448 
exceed 55% in either case, all of the available release values were included in the 449 
calculations. Based on these results, calculated f2 values were 98.5 for release into 450 
IPA+H2O and 94.9 for release into SVF+Tween, both well above the value of 50 often 451 
used to indicate similarity. Interestingly, the in vitro cumulative release levels obtained 452 
with SVF+Tween over a 30-day period for both the form I and form IV rings were similar 453 
to 28-day in vivo release levels observed with IPM’s 25 mg DPV matrix ring 004 (~4 454 
mg).33,39 This indicates that the SVF+Tween release media more closely mimics the 455 
amount of drug released in vivo than either SVF alone or the IPA+H2O medium.  456 
 457 
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3.8. Content and residual content 458 
Initial dapivirine content in the rings post-manufacture was 24.87 ± 0.16 and 25.82 ± 0.28 459 
mg for rings containing form I and form IV dapivirine, respectively (equivalent to 99.5 and 460 
103.3% of the nominal content value), as measured by a solvent extraction method, and 461 
highlighting the consistency of the manufacturing process. Following completion of in 462 
vitro release testing, all rings were tested for residual dapivirine content. The residual 463 
content values were then combined with the cumulative release values and compared to 464 
initial ring content values to assess mass balance. The data presented in Table 6 465 
demonstrate almost identical cumulative release between the two polymorphs of 13.1 mg 466 
and 4.5 mg into IPA+H2O and SVF+Tween over 30 days. The amounts of DPV recovered 467 
after in vitro release testing are also consistent with the slightly higher initial loading in the 468 
rings containing form IV DPV compared to those containing form I. Thus, the calculated 469 
initial loadings for each polymorph are higher for form IV at approximately 25.8 mg, 470 
compared to form I at approximately 25.0 mg. These values fit very well with the initially 471 
calculated content values of 25.8 mg and 24.9 mg for form IV and form I respectively.  472 
 473 
3.9. DPV solubility  474 
DPV, with an experimental pKa value of 5.54,46 exhibits the typical weak base behaviour 475 
of increased solubility as pH is lowered (Figure 8). Moreover, the solubility vs. pH profiles 476 
are very similar for polymorphic forms I and IV, within the limits of experimental error. 477 
The lower solubility values at pH 1 are due to the common ion effect (i.e. chloride ions) 478 
associated with increased concentration of hydrochloric acid. Based on these in vitro 479 
solubility data, DPV solubility at vaginal pH values typical of women of reproductive age 480 
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(typically between 3.5 and 7; the higher values are common with certain vaginal infections 481 
and in the presence of semen43,57) would lie within the range 0–15 µg/mL, which goes some 482 
way to explaining the wide variation in DPV pharmacokinetics measured in women during 483 
ring use.14,28,53–55  484 
 485 
Experimentally determined values of thermodynamic solubility for DPV forms I and IV – 486 
micronised and non-micronised materials, and measured in both 1:1 v/v IPA/water and 487 
SVF+0.2% w/v Tween 80 – are presented in Table 8. As expected, DPV solubility in 488 
IPA/water (~1200 µg/mL) is significantly greater (by a factor of ~75) compared with 489 
solubility measured in SVF/Tween (~16 µg/mL). That in vitro DPV release from vaginal 490 
rings into these two release media does not differ by a similar factor is a consequence of 491 
the permeation-controlled release kinetics that apply to silicone elastomer vaginal rings, 492 
wherein molecular diffusion of drug through the silicone matrix is rate controlling.51 The 493 
data also clearly illustrate that neither DPV particle size nor the polymorphic form of DPV 494 
influence the thermodynamic solubility value, irrespective of the release medium tested. 495 
PXRD analysis of the residual DPV material after preparation of saturated solutions 496 
confirmed the no form conversion was observed during the solubility analysis and 497 
indicating that the results reflect the true solubility of each form (Table 8).    498 
 499 
4. Conclusions 500 
This is the first report of the impact of drug polymorphism on the performance 501 
characteristics of a vaginal ring device. DPV form I and form IV polymorphs were 502 
distinguished using DSC, PXRD and solubility analyses. TGA demonstrated that both 503 
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polymorphs were thermally stable over the range of processing temperatures likely to be 504 
encountered during manufacture. Particle size analysis revealed a similar size distribution 505 
for micronized versions of both polymorphs whereas the non-micronized form I average 506 
particle size was slightly larger than form IV. Manufacture of silicone elastomer rings 507 
nominally containing 25 mg DPV produced rings with a mean content with 5% of the 508 
nominal value for both polymorphs. In vitro release testing of rings showed a very similar 509 
release profile for both polymorphs with similarity factor f2 values greater than 90. An 510 
increase in the day 1 to day 3 release for the form IV polymorph compared to the form I 511 
polymorph was observed. Possible explanations for this difference include variations in 512 
dissolution rates between the two polymorphs and or different surface distributions from 513 
manufacture. DPV mass balance was achieved from residual content values plus the 514 
cumulative release values recorded into each media. Release of DPV into SVF+Tween 515 
over 30 days more closely matches the amount of DPV released in vivo over a similar time 516 
period than either IPA+H2O or SVF only. Finally, no significant differences in 517 
thermodynamic solubility were observed for the various particle size and polymorphic 518 
forms of DPV.   519 
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 724 
Figure 1. Summary of the relationships between the crystalline and amorphous 725 
polymorphic forms of dapivirine. DCM = dichloromethane. Forms I and IV were 726 
characterized by thermogravimetric analysis (TGA), differential scanning calorimetry 727 
(DSC), polarized light microscopy, hot stage microscopy, x-ray powder diffraction 728 
(XRPD), variable temperature XRPD (VT-XRPD) and single crystal x-ray diffraction. 729 
Both forms were also tested by gravimetric vapour sorption (GVS) to assess 730 
hygroscopicity, as well as solubility in common aqueous and organic solvents. 731 
[Unpublished data; IPM].   732 
 33 
  733 
Figure 2. Representative DSC traces of non-micronized DPV (A) form I and (B) form IV. 734 
For clarity, heat flow values between -0.4 and 0.4 are displayed, such that some peaks are 735 
truncated. Values of the enthalpies associated with each endotherm and exotherm are 736 
presented in Table 1. The second heat cycle for form IV has been offset by -0.1 W/g to aid 737 
visualisation.  738 
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 739 
Figure 3. Measured particle size distribution of DPV form I and form IV. (A) non-740 
micronized powders; (B) micronized powders.   741 
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 742 
Figure 4. Powder XRD traces for (A) non-micronized DPV form I, (B) micronized DPV form I, 743 
(C) non-micronized DPV form IV, and (D) micronized DPV form IV. Data is presented in the 2θ 744 
angular range of 3 to 50°. Two peaks in A, at 2θ = 5.2 and 10.3 degrees, have been truncated to 745 
allow better comparison of the traces.   746 
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 747 
  748 
  749 
 750 
Figure 5. Representative micrographs recorded at 200x magnification of non-micronized DPV 751 
form I (A), form IV (B), and micronized DPV form I (C) and form IV (D).  752 
 37 
 753 
Figure 6. Mean maximum force required to compress each ring formulation (n=5 per batch).  754 
 38 
 755 
Figure 7. Mean daily release versus time profiles for release into (A) IPA+H2O and (B) 756 
SVF+Tween, and cumulative release versus root time profiles for release into (C) IPA+H2O and 757 
(D) SVF+Tween, of DPV from MED-4870 matrix-type vaginal rings containing DPV (either form 758 
I or form IV, 25 mg per ring) over 30 days. Error bars in graphs A and B represent standard 759 
deviation of twelve replicates; error bars were often smaller than the plot symbol. A small deviation 760 
from the otherwise very consistent drug release profile is present on day 22 of the release into 761 
SVF+Tween (B and D). This was due to an extended weekend release period without replacement 762 
of release medium. 763 
  764 
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 765 
Figure 8. pH versus solubility profiles for DPV forms I and IV. Plot symbols represent the mean 766 
of four replicates; error bars representing ± standard deviation are smaller than the plot symbols.  767 
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Table 1. Mean peak onset temperature (°C), peak temperature (°C) and enthalpy (ΔH, J/g) values 768 
for each thermal transition associated with micronized and non-micronized DPV forms I and IV. 769 
Endothermic transitions 1 & 2 are observed during the 1st heat cycle, endothermic transitions 3 & 770 
5 and exothermic transition 4 are observed during the 2nd heat cycle.  771 
 772 
DPV  
material *  
Transition 
No. 
Onset  
(˚C) 
Peak Maximum 
(˚C) 
Enthalpy 
 (ΔH, J/g) 
Assignment 
form I (m) 1 101.1 104.1 8.0 I→II 
form I (nm) 1 97.8 99.3 10.4 I→II 
form IV (nm)   1 205.8 209.3 10.9 IV→II 
form IV (m)   1 189.4 199.0 8.0 IV→II 
form I (m) 2 219.9 221.9 114.7 
IImelting 
form I (nm) 2 219.9 221.9 119.2 
form IV (nm)   2 220.0 221.8 121.9 
form IV (m)   2 220.1 221.8 104.2 
form I (m) 3 80.9 85.6 1.6 
Tg with 
amorphous 
relaxation 
form I (nm) 3 80.9 85.5 1.8 
form IV (nm)   3 81.2 85.6 1.4 
form IV (m)   3 81.2 85.7 1.6 
form I (m) 4 163.0 167.9 -82.9 
Recrystallization 
to form II 
form I (nm) 4 159.8 167.4 -87.4 
form IV (nm)   4 154.4 163.0 -87.4 
form IV (m)   4 153.8 164.8 -68.4 
form I (m) 5 219.6 221.9 112.8 
II melting 
form I (nm) 5 219.5 221.7 117.0 
form IV (nm)   5 219.7 221.9 118.1 
form IV (m)   5 219.8 221.9 100.2 
* nm – non-micronized, m – micronized   773 
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Table 2. Experimentally determined d90, d50 and d10 values for both non-micronized and 774 
micronized DPV form I and form IV materials with comparative certificate of analysis values 775 
where available. 776 
 777 
 778 
 779 
 780 
 781 
 782 
* nm – non-micronized, m – micronized; # CoA – certificate of analysis  783 
DPV Batch * 
Experimentally Determined 
Particle Size (µm)  
CoA# Specified Particle Size 
(µm) 
d90 d50 d10  d90 d50 d10 
form I (nm) 324 111 22.1  302 101 19 
form I (m) 14.7 6.00 2.20  14.0 5.9 2.0 
form IV (nm)   250 74.4 17.8  N/A N/A N/A 
form IV (m)   14.5 5.00 1.58  14.6 4.82 0.551 
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Table 3. Mean ring weight, external diameter and cross-sectional diameter for five rings assessed 784 
from each micronized DPV manufacturing batch. 785 
 786 
DPV polymorph 
(Batch No.) 
Ring Weight 
(Mean ± SD; g) 
C.S.D. (Mean ± 
SD; mm) 
Mean Ex.D. ± SD 
(mm) 
form I (B1) 7.93 ± 0.24 7.58 ± 0.10 56.41 ± 0.04 
form I (B2) 7.99 ± 0.01 7.62 ± 0.01 56.41 ± 0.03 
form IV (B1) 7.99 ± 0.06 7.62 ± 0.01 56.39 ± 0.02 
form IV (B2) 8.05 ± 0.01 7.62 ± 0.02 56.39 ± 0.02 
B1 – batch 1, B2 – batch 2; acceptable limits for weight (7.2 – 8.8 g), external diameter (Ex.D.; 54.9 – 57.1 mm) and 787 
cross sectional diameter (C.S.D.; 7.3 – 8.1 mm). 788 
  789 
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Table 4. Mean Shore A hardness measurement for five rings assessed from each micronized DPV 790 
manufacturing batch. 791 
 792 
Batch Details Shore A Hardness ± SD (arbitrary units) 
DPV form I (B1) 64.9 ± 1.0 
DPV form I (B2) 65.1 ± 0.5 
DPV form IV (B1) 65.1 ± 0.3 
DPV form IV (B2) 65.7 ± 0.2 
   B1 – batch 1, B2 – batch 2 793 
  794 
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Table 5. Release rates and coefficients of correlation (r2) obtained from linear regression analysis 795 
of the cumulative DPV release vs. root time plots for matrix-type vaginal rings containing different 796 
forms of micronized DPV released into IPA+H2O or SVF+Tween. 797 
 798 
DPV type Release medium Release rate (µg/day 0.5) r2 value 
form I IPA+H2O 2330 0.9983 
form IV IPA+H2O 2323 0.9980 
form I SVF+Tween 959.9 0.9823 
form IV SVF+Tween 887.8 0.9880 
form I SVF+Tween (day 8-30) 1146.4 0.9993 
form IV SVF+Tween (day 8-30) 1027.5 0.9995 
  799 
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Table 6. Thermodynamic solubility values for DPV forms I and IV, micronized and non-800 
micronized, into SVF + 0.2%Tween 80 and 1:1 v/v IPA/water. Both release media have been 801 
used routinely throughout the development process for the DPV-releasing vaginal ring. 802 
Solubility values are reported as mean ± SD of n=4 replicates. 803 
 804 
DPV 
polymorph Solvent system 
DPV solubility at 37 °C 
(Mean ± SD; μg/mL) 
PXRD analysis of 
residual solid 
form I (nm) SVF + 0.2% (w/v) Tween 80 16.78 ± 0.66 form I 
form I (m) SVF + 0.2% (w/v) Tween 80 16.12 ± 0.29 form I 
form I (nm) IPA/water (1:1 v/v) 1171 ± 53 form I 
form I (m) IPA/water (1:1 v/v) 1249 ± 46 form I 
form IV (nm) SVF + 0.2% (w/v) Tween 80 14.74 ± 0.99 form IV 
form IV (m) SVF + 0.2% (w/v) Tween 80 15.83 ± 0.14 form IV 
form IV (nm) IPA/water (1:1 v/v) 1193 ± 36 form IV 
form IV (m) IPA/water (1:1 v/v) 1214 ± 34 form IV 
  805 
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 806 
Table 7. Amount of DPV released, residual DPV content and calculated initial content values for 807 
25 mg (nominally) DPV polymorph rings. 808 
 809 
DPV 
polymorph Release medium DPV released (mg) Residual DPV (mg) 
Calculated initial 
DPV content (mg) 
form I IPA+H2O 13.1 ± 0.2 12.0 ± 0.3 25.1 ± 0.4 
form IV IPA+H2O 13.1 ± 0.5 12.6 ± 0.3 25.7 ± 0.3 
form I SVF+Tween 4.6 ± 0.1 20.3 ± 0.4 24.9 ± 0.3 
form IV SVF+Tween 4.5 ± 0.4 21.3 ± 0.4 25.9 ± 0.5 
 810 
